COSCIENS Biopharma’s Unexpected Trial Outcomes

COSCIENS Biopharma (TSE:CSCI) has released an update.

COSCIENS Biopharma Inc. revealed unexpected Phase 3 trial results for macimorelin, a diagnostic tool for Childhood Onset Growth Hormone Deficiency, which did not meet the primary efficacy endpoint. Despite this, the trial confirmed the safety of macimorelin and its ability to stimulate growth hormone release in children. The company plans further analysis and discussions with health authorities while continuing to market macimorelin for adult use.

For further insights into TSE:CSCI stock, check out TipRanks’ Stock Analysis page.